Key result
Right-sided St. Jude Medical valves linked to ~6-fold more valve-related events than bioprosthetic valves.
Why the study?
Does the St. Jude Medical valve compared to bioprosthetic valves improve outcomes in patients undergoing right-sided heart valve replacement?
Cohort (n=54)
Does the St. Jude Medical valve compared to bioprosthetic valves improve outcomes in patients undergoing right-sided heart valve replacement?
Bioprosthetic valves demonstrated superior long-term durability and lower complication rates compared to St. Jude Medical mechanical valves for right-sided heart valve replacement.
Answers are grounded in this paper and cite their sources.
May support bioprosthetic preference for right-sided positions; leaves open confirmation in contemporary randomized data.
Comparative long-term performance characteristics of St. Jude Medical (SJM) and bioprosthetic valves were conducted retrospectively for patients who underwent prosthetic valve replacement in the right side of the heart from 1975 to 1988. Fifty-four patients received either SJM (n = 18) or bioprosthetic (n = 37) valves. The cumulative follow-up for SJM valves was 91 valves-years (range 3.9 to 7.2 years) and that for bioprostheses was 282 valve-years (range 1.3 to 14.8 years). Follow-up rate was 100%. The actuarial survival rate excluding hospital deaths at 5 years was 81 +/- 10% for SJM and 97 +/- 3% for bioprosthetic valve recipients (p = ns). The rates of freedom from thrombosis or anticoagulant-related hemorrhage, structural valve failure, prosthetic valve endocarditis, reoperation, and overall valve-related complications at 5 years were 72 +/- 11%, 100%, 100%, 83 +/- 9%, and 72 +/- 11% for SJM valve recipients, and 100%, 97 +/- 3%, 97 +/- 3%, 94 +/- 4%, and 94 +/- 4% for bioprosthetic valve recipients, respectively. Structural valve failure, prosthetic valve endocarditis and reoperations occurred at a similar incidence in each of the two types of prostheses. Thrombosis and overall valve-related events occurred more frequently in SJM valve recipients (5.5 +/- 2.5 vs 0%/valve-year; p less than 0.02, 6.6 +/- 2.7 vs 1.1 +/- 0.6 %/valve-year; p less than 0.03, respectively). The bioprosthetic valve which did not need warfarin anticoagulation therapy had low incidence of valve-related complications and showed good long-term durability even in the younger age group. The bioprosthetic valve was superior to the SJM valve in the right side of the heart.
No takes yet. Share an insight, caveat, or question.
Kawachi et al. (1991) conducted a cohort in Prosthetic valve replacement in the right side of the heart (n=54). St. Jude Medical (SJM) valve vs. Bioprosthetic valve was evaluated on Overall valve-related events (p=<0.03). St. Jude Medical valves in the right side of the heart were associated with higher rates of overall valve-related events compared to bioprosthetic valves.
Synapse has enriched 10 related papers. Consider them for comparative context: